# Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

> **NCT00171834** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 89 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Patupilone

## Key facts

- **NCT ID:** NCT00171834
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2014-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171834, "Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00171834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*